share_log

Clearmind Medicine | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Clearmind Medicine | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Clearmind Medicine | 6-K：外國發行人報告
SEC announcement ·  04/10 16:03
Moomoo AI 已提取核心訊息
Clearmind Medicine Inc., a clinical-stage biotech company, has announced the filing of a U.S. patent application for a novel psychedelic-based treatment aimed at eating disorders. The treatment involves the use of 3-methylmethcathinone (3-MMC) either alone or in combination with Palmitoylethanolamide (PEA). The company, listed on Nasdaq and the Frankfurt Stock Exchange, is positioning itself at the forefront of the weight loss pharmaceutical sector, which is projected to grow significantly due to rising obesity rates worldwide. Clearmind's patent application is part of its broader strategy to develop and commercialize psychedelic-derived therapeutics for major health issues, including alcohol use disorder. The company's intellectual property portfolio currently includes sixteen patent families. The announcement was made on April 10, 2024, and the information was also incorporated by reference into Clearmind's Registration Statements on Form F-3 with the SEC.
Clearmind Medicine Inc., a clinical-stage biotech company, has announced the filing of a U.S. patent application for a novel psychedelic-based treatment aimed at eating disorders. The treatment involves the use of 3-methylmethcathinone (3-MMC) either alone or in combination with Palmitoylethanolamide (PEA). The company, listed on Nasdaq and the Frankfurt Stock Exchange, is positioning itself at the forefront of the weight loss pharmaceutical sector, which is projected to grow significantly due to rising obesity rates worldwide. Clearmind's patent application is part of its broader strategy to develop and commercialize psychedelic-derived therapeutics for major health issues, including alcohol use disorder. The company's intellectual property portfolio currently includes sixteen patent families. The announcement was made on April 10, 2024, and the information was also incorporated by reference into Clearmind's Registration Statements on Form F-3 with the SEC.
臨床階段的生物技術公司Clearmind Medicine Inc. 宣佈申請一項針對飲食失調的新型迷幻藥療法的美國專利。該治療包括單獨使用3-甲基甲卡西酮（3-MMC）或與棕櫚酰乙醇胺（PEA）聯合使用。該公司在納斯達克和法蘭克福證券交易所上市，正處於減肥製藥行業的最前沿，由於全球肥胖率的上升，預計減肥藥業將大幅增長。Clearmind的專利申請是其針對主要健康問題（包括酒精使用障礙）開發和商業化迷幻藥衍生療法的更廣泛戰略的一部分。該公司的知識產權組合目前包括十六個專利家族。該公告於2024年4月10日發佈，該信息還以引用方式納入了Clearmind向美國證券交易委員會提交的F-3表格註冊聲明。
臨床階段的生物技術公司Clearmind Medicine Inc. 宣佈申請一項針對飲食失調的新型迷幻藥療法的美國專利。該治療包括單獨使用3-甲基甲卡西酮（3-MMC）或與棕櫚酰乙醇胺（PEA）聯合使用。該公司在納斯達克和法蘭克福證券交易所上市，正處於減肥製藥行業的最前沿，由於全球肥胖率的上升，預計減肥藥業將大幅增長。Clearmind的專利申請是其針對主要健康問題（包括酒精使用障礙）開發和商業化迷幻藥衍生療法的更廣泛戰略的一部分。該公司的知識產權組合目前包括十六個專利家族。該公告於2024年4月10日發佈，該信息還以引用方式納入了Clearmind向美國證券交易委員會提交的F-3表格註冊聲明。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息